logo

For the Inventor, By the Inventor

Parkville, Australia

Csl Limited


USPTO Granted Patents = 122



Trademarks = 32

Forward Citations = 605

Loading Chart...
Loading Chart...

154 inventors (with patents filed for the assignee):

goldMedal Andrew Donald Nash (19 out of 29 patents)

silverMedal Con Panousis (15 out of 18 patents)

bronzeMedal Gary Lee Warren (11 out of 11 patents)

4.  Yvonne Vucica (11 out of 11 patents)

5.  Manuel Baca (11 out of 33 patents)

6.  Veronika Rayzman (9 out of 9 patents)

7.  Michael Wilson (7 out of 10 patents)

8.  Marc Nolte (7 out of 23 patents)

9.  William Strohl (7 out of 29 patents)

10.  Kirsten Edwards (7 out of 7 patents)

11.  Hubert Metzner (7 out of 28 patents)

12.  Louis Jerry Fabri (7 out of 16 patents)

13.  Zhiqiang An (7 out of 39 patents)

14.  Ian George Barr (7 out of 8 patents)

15.  Dennis M Zaller (7 out of 10 patents)


Core Competencies:
Asthma Treatment
Granulocyte-Colony Stimulating Factor
Reconstituted HDL Formulation
Factor VIII Stability
Chronic Kidney Disease
Diabetic Nephropathy
Apolipoprotein A-I
Stroke Treatment
Interleukin-13 Antagonists
Vascular Endothelial Growth Factor
Von Willebrand Factor
Neurological Inflammatory Disorders

122 patents:

1. 12281160 - Method of treating asthma (2025-04-21),
2. 12264202 - Methods of reducing or hindering development of ischemia-reperfusion injury due to kidney transplantation with an antibody that inhibits granulocyte-colony stimulating factor (G-CSF) signaling (2025-04-01),
3. 12071484 - Nucleic acids encoding antibodies against human granulocyte-colony stimulating factor receptor (G-CSFR) and method of expressing encoded protein (2024-08-27),
4. 11957731 - Reconstituted HDL formulation (2024-04-16),
5. 11840573 - CD131 binding proteins and uses thereof (2023-12-12),
6. 11732028 - Contaminant removal method (2023-08-22),
7. 11723953 - Reconstituted high density lipoprotein formulation and production method thereof (2023-08-15),
8. 11510968 - Method for improving the stability of purified Factor VIII after reconstitution (2022-11-29),
9. 11505619 - Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease (2022-11-22),
10. 11466073 - Human serum albumin variants and uses thereof (2022-10-11),
11. 11464828 - Reconstituted HDL formulation (2022-10-11),
12. 11345759 - Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies (2022-05-31),
13. 11279750 - Process for preparing apolipoprotein A-I (Apo A-I) (2022-03-22),
14. 11261243 - Methods of treating diabetic nephropathy by administering an anti-vegf-b (vascular endothelial growth factor-b) antibody (2022-03-01),
15. 11174321 - Method of treating atherosclerosis (2021-11-16),
CSL Limited is a global biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious medical conditions. With operations in over 30 countries and a diverse product portfolio, CSL's focus areas include vaccines, plasma protein biotherapeutics, and recombinant proteins. The company is committed to advancing innovative solutions in healthcare and improving patient outcomes.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

...
122 Patents

#1 in Parkville

#23 in Australia

#6,356 in the World

...
Parkville, Australia

Csl Limited

Forward Citations = 605

154 inventors:

goldMedal Andrew Donald Nash (19 out of 29 patents)

silverMedal Con Panousis (15 out of 18 patents)

bronzeMedal Gary Lee Warren (11 out of 11 patents)

4.  Yvonne Vucica (11 out of 11 patents)

5.  Manuel Baca (11 out of 33 patents)

Please report any incorrect information to support@idiyas.com
Loading…